Pfizer COVID shots appear 73% effective in children under 5
Pfizer’s says its COVID-19 vaccine was 73% effective in protecting children younger than 5 as omicron spread in the spring
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Pfizer's COVID-19 vaccine was 73% effective in protecting children younger than 5 as omicron spread in the spring, the company announced Tuesday.
Vaccinations for babies, toddlers and preschoolers opened in the U.S. in June after months of delay. Only about 6% of youngsters ages 6 months through 4 years had gotten at least one dose of a COVID-19 vaccine by mid-August, according to the American Academy of Pediatrics.
Health authorities authorized tot-sized vaccine doses made by Pfizer and its partner BioNTech based on a study showing they were safe and produced high levels of virus-fighting antibodies. But there was only preliminary data on how that translated into effectiveness against symptomatic COVID-19.
The new update analyzed COVID-19 diagnoses between March and June in Pfizer's ongoing study of the three-dose vaccine. There were 21 COVID-19 cases among the 351 tots who got dummy shots -- compared to just 13 among the 794 youngsters given three vaccine doses.
The child cases primarily were caused by the BA.2 omicron version that was circulating at the time. Today, another omicron relative, BA.5, is causing most COVID-19 cases in the U.S. and much of the world.
In older children and adults, the COVID-19 vaccines have been used long enough to prove that they remain strongly protective against severe disease and death even as the coronavirus mutates -- while early protection against infection wanes. Still, scientists track that initial effectiveness rate as extra evidence of vaccine performance -- and to look for signs of how they initially hold up against new mutants.
Pfizer this week asked U.S. regulators to authorize modified vaccine doses that better match the newest omicron variants for people 12 and older as boosters this fall. The company said it also is developing updated shots for kids under 12.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.